Inbrija Capsule
Product Images NDC 10144-342

Product Visual Gallery

This gallery contains 30 technical images submitted to the FDA as part of the official labeling for Inbrija (NDC 10144-342). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merz Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Inbrija 01)

Chemical structure of levodopa, the active ingredient in Inbrija 42 mg inhalation capsules by Merz Pharmaceuticals, LLC. The diagram shows the molecular formula with hydroxyl groups, an amino group, and a carboxyl group attached to a benzene ring structure.*

FDA Label Image

Figure 1 (Inbrija 02)

A line graph showing least-square mean ± SE over time post dose (minutes) comparing Inbrija 84 mg (N=114) and placebo (N=112). The graph demonstrates a decrease over 60 minutes with Inbrija displaying a greater reduction than placebo.*

FDA Label Image

Figure A (Inbrija 03)

Illustration of the Inbrija levodopa inhalation powder device components highlighting the blue handle, capsule chamber containing the capsule, white mouthpiece with alignment arrows, and blue cap. This diagram visually identifies parts of the respiratory capsule device for inhalation use.*

FDA Label Image

Figure B (Inbrija 04)

The image shows the packaging label for Inbrija 42 mg capsules, which contain levodopa inhalation powder. The label features two capsules per full dose for oral inhalation only, marked A42. It includes usage instructions, expiration, and lot number fields. The labeler is Merz Pharmaceuticals, LLC, and the NDC is 10144-342.*

FDA Label Image

Figure C (Inbrija 05)

Inbrija 42 mg capsules blister pack label showing levodopa inhalation powder. The label indicates a 42 mg strength per capsule with a pack of 2 capsules designed for oral inhalation use. The labeler is Merz Pharmaceuticals, LLC. The pack includes instructions such as 'Do not swallow capsule' and 'For use with Inbrija inhaler only.'*

FDA Label Image

Figure D (Inbrija 06)

An illustration showing two elongated capsules positioned vertically with a plus sign between them, labeled as Fig. D. The capsules are plain white with a scored line in the center, displayed against a white background. This diagram likely depicts the capsule form associated with the inhalation drug Inbrija.*

FDA Label Image

Figure E (Inbrija 07)

An illustration showing hands tearing off a packaging strip containing two Inbrija levodopa capsules. The packaging displays the product name Inbrija, strength 42 mg per capsule, dosage form as capsules, and denotes full dose of 2 capsules. The illustration is labeled as Fig. E and demonstrates how to open the package for inhalation use.*

FDA Label Image

Figure F (Inbrija 08)

An instructional figure titled 'Check Expiration Date' (Fig. F) showing blister card segments for 42 mg capsules of Inbrija (levodopa). The diagram highlights where to find the expiration date (EXP: MMYYYY) and lot number (Lot:) printed on the blister pack, with peel tabs visible at the bottom of each segment.*

FDA Label Image

Figure G (Inbrija 09)

Illustration showing how to remove the cap from an Inbrija levodopa inhalation capsule device by pulling the cap off, indicated with a red arrow pointing to the right. The partial device and capsule are shown in blue and white colors.*

FDA Label Image

Figure H (Inbrija 10)

Illustration showing proper use of the Inbrija inhalation device with levodopa powder capsules. The image demonstrates twisting and pulling off the mouthpiece from the device as part of the preparation steps before inhalation.*

FDA Label Image

Figure I (Inbrija 11)

An instructional illustration showing the removal of one Inbrija 42 mg levodopa capsule from its blister packaging. The image demonstrates hands peeling back the foil to access the capsule inside the package, with arrows indicating the peeling motion.*

FDA Label Image

Figure J (Inbrija 12)

An instructional diagram showing how to load one capsule into the chamber of the inhalation device for Inbrija (levodopa) 42 mg capsule. The illustration depicts a hand placing a capsule into the top opening of the inhaler, with a close-up inset of the chamber's interior.*

FDA Label Image

Figure K (Inbrija 13)

Instructional illustration showing a user aligning arrows on the mouthpiece and handle of an Inbrija levodopa inhalation capsule device to prepare it for use.*

FDA Label Image

Figure L (Inbrija 14)

An instructional diagram labeled Fig. L showing two hands compressing the mouthpiece of a device once, indicated by the word "click" in black starburst. Red arrows point inward toward the compressed area, illustrating the action of pressing the mouthpiece together, part of inhalation device use instructions.*

FDA Label Image

Figure M (Inbrija 15)

An instructional illustration labeled 'Release Mouthpiece Fig. M' showing a hand holding a device with the mouthpiece being released by sliding a blue component backward. A check mark indicates the correct action.*

FDA Label Image

Figure N (Inbrija 16)

Instructional illustration showing a person holding an Inbrija inhaler near their mouth, exhaling outward as directed by the label text 'Hold Inhaler Away And Breathe Out.' The image demonstrates proper use of the inhalation device for levodopa capsules.*

FDA Label Image

Figure O (Inbrija 17)

An instructional illustration showing a person using a respiratory inhalation capsule device. The image demonstrates inhaling deeply to inhale the powder, with a 'whirl' sound effect depicted near the inhaler mouthpiece and arrows indicating airflow through the mouth.*

FDA Label Image

Figure P (Inbrija 18)

An instructional illustration showing a side profile of a person with a stopwatch indicating to hold their breath for 5 seconds, followed by breathing out. The image includes the text "Hold Breath For 5 Seconds, Then Breathe Out" and is labeled as Figure P.*

FDA Label Image

Figure Q (Inbrija 19)

Instructional illustration showing how to use the Inbrija levodopa inhalation capsule by twisting and pulling off the mouthpiece, labeled as Figure Q.*

FDA Label Image

Figure R (Inbrija 20)

An instructional illustration showing a hand holding a used capsule, labeled with the direction to 'Remove Used Capsule.' This figure is identified as 'Fig. R,' likely part of a step-by-step guide for using Inbrija inhalation capsules.*

FDA Label Image

Figure S (Inbrija 21)

Illustration showing hands removing a capsule from a blister pack, indicating to repeat steps with the second capsule. This instructional diagram is part of usage directions for Inbrija levodopa 42 mg respiratory inhalation capsules by Merz Pharmaceuticals.*

FDA Label Image

Figure T (Inbrija 22)

An instructional illustration showing a hand dropping two used capsules into a waste container labeled "Household Trash." The image is titled "Throw Out Used Capsules" and is identified as Fig. T.*

FDA Label Image

Figure U (Inbrija 23)

An instructional illustration demonstrating how to clean the mouthpiece of the Inbrija levodopa inhalation capsule device from the top end. It shows hands using a cotton swab or similar tool to clean the inside of the mouthpiece, with arrows indicating a circular cleaning motion.*

FDA Label Image

Inbrija 23a

Illustration showing instructions to clean the mouthpiece of an inhalation device from the bottom end. The image depicts hands removing or cleaning the mouthpiece with a swab or cotton tip, indicating rotational movement for proper cleaning.*

FDA Label Image

Figure V (Inbrija 24)

Instructional illustration showing how to attach a mouthpiece to the Inbrija levodopa inhalation capsule device. The image depicts a hand holding the mouthpiece aligned with the device, with an arrow indicating the direction to connect the mouthpiece.*

FDA Label Image

Inbrija 24a

Illustration showing how to attach the cap on the Inbrija levodopa inhalation capsule inhaler device. The image depicts hands aligning and pressing the cap into place with directional arrows indicating the motion for proper attachment.*

FDA Label Image

Figure W (Inbrija 25)

Illustration showing the Inbrija levodopa inhalation capsule device in a 'Ready For Storage' position. The device is blue and labeled with the proprietary name Inbrija, indicating it contains levodopa inhalation powder. A check mark confirms the correct storage position.*

FDA Label Image

Principal Display Panel (42 mg Capsule Blister Pack Carton)

Packaging label for Inbrija 42 mg capsules, containing levodopa inhalation powder for oral inhalation only. The label shows the product name, dosage strength, and capsule form, with a yellow and white color scheme. It includes contents of 60 capsules, prescribing information, and warnings not to swallow the capsules. Labeler information is Merz Pharmaceuticals, LLC, with NDC 10144-342-60 visible.*

FDA Label Image

Inbrija 27

Packaging label for Inbrija 42 mg capsules, levodopa inhalation powder for oral inhalation only. The label shows a white and yellow gradient background with the product name, active ingredient, strength, and usage directions. It states "Do not swallow Inbrija capsules" and provides storage instructions. The label also includes the NDC 10144-342 and the manufacturer, Merz Pharmaceuticals, LLC.*

FDA Label Image

Inbrija 28

Packaging label for Inbrija 42 mg capsules, a levodopa inhalation powder for oral inhalation only. The label includes the proprietary name Inbrija, strength 42 mg, dosage form capsules, and instructions not to swallow the capsules. The manufacturer is Merz Pharmaceuticals, LLC, with product NDC 10144-342. The label features yellow and white gradient background with product and usage information, barcode, and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.